CHD Vendée
- Address
- Boulevard Stéphane Moreau, Vendée, 85000 La Roche sur Yon, France
CHD Vendée - Lung Cancer Research
CHD Vendée is actively engaged in advanced oncology research, with a particular emphasis on Non-Small Cell Lung Cancer (NSCLC) treatment strategies. The center participates in cutting-edge Phase II-III clinical trials investigating optimal maintenance therapy approaches following platinum-based chemotherapy regimens combined with immunotherapy.
- Stage IV Non-Small Cell Lung Cancer treatment optimization
- Pembrolizumab maintenance therapy evaluation
- Platinum-based chemotherapy and immunotherapy combination strategies
The center's research focuses on determining the most effective duration and combination of pembrolizumab maintenance treatment, comparing continuous immunotherapy with observation strategies after initial induction therapy. This work addresses critical questions in lung cancer management, including tailored approaches for both squamous and non-squamous carcinoma subtypes, with the potential to significantly impact treatment protocols for patients with advanced-stage lung cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHD Vendée
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Open-Label, Superiority Trial Comparing Subcutaneous Abatacept and Tocilizumab in Rheumatoid Arthritis Patients with Inadequate Response to Targeted Therapies | Groupement Des Hopitaux De L'Institut Catholique De Lille | Phase III | Not Recruiting | Jan 2018 | Jan 2026 |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 2 | Unknown | 2020-11-03 | 2022-05-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.